Generic Name:
luspatercept
Project Status:
Complete
Therapeutic Area:
beta-thalassemia associated anemia
Manufacturer:
Celgene Inc. / Bristol-Myers Squibb Canada Co.
Brand Name:
Reblozyl
Project Line:
Reimbursement Review
Project Number:
SR0669-000
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with -thalassemia associated anemia who require red blood cell (RBC) transfusions.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adult patients with
red blood cell (RBC) transfusion-dependent anemia associated with
beta(β)-thalassemia
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.